On July 29th, U.S. Senator Richard Durbin (D-IL) introduced the Dietary Supplement Listing Act of 2024.
The act would require dietary supplement manufactures to list their products with the FDA.
In addition to product listing, the law would also require information such as a complete list of ingredients, an electronic copy of the label, allergen statements, health and function claims, and more.
Senator Durbin, a long-time advocate for increased oversight of the supplement industry, previously pushed for Mandatory Product Listing (MPL) in 2022, though that legislation did not pass Congress.
The Senator’s press release provides background on the law’s ostensible intent:
“More than 75 percent of American adults use a dietary supplement. However, no product is without risk.
In 2023, FDA received more than 2,000 adverse event reports related to dietary supplements. However, due to significant underreporting, FDA has estimated the actual annual number of adverse events is more than 50,000.”
The dietary supplement industry has grown from a $4 billion industry to $30 billion in 30 years, and MPL would have massive implications for the industry.
While many people recognize regulatory oversight as a means to ensure consumer safety, many in the industry wonder whether FDA has the resources to enforce this legislation. Others voice concerns it could stifle innovation and raise prices.
Microchem will continue to monitor and provide updates as dietary supplement regulations evolve and change.
